CDKN2A and cancer: ANRIL has been proven to play a prime function in promoting transcriptional suppressors concerned within the discount of CDKN2A / B genes, leading to the genetic predisposition to diverse cancers (Congrains et al., 2013 [20]; Yap et al., 2010 [43]; Popov & Gil, 2010 [44]).